We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+27.98%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$300M
AUM Growth
+$102M
Cap. Flow
+$5.36M
Cap. Flow %
1.79%
Top 10 Hldgs %
74.87%
Holding
29
New
7
Increased
5
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$32.6M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$17.9M
3
DCOY
Decoy Therapeutics
DCOY
+$15.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$6.36M
5
TVTX icon
Travere Therapeutics
TVTX
+$6.25M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.3M
2
MGNX icon
MacroGenics
MGNX
+$15.9M
3
KITE
Kite Pharma, Inc.
KITE
+$10.5M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$9.98M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KERX
26
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-589,000
Closed -$8.33M
VTAE
27
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-207,000
Closed -$3.44M
OMED
28
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-157,038
Closed -$3.42M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2015 Portfolio in Review

As of Q1 2015, EcoR1 Capital held 29 positions worth $300M, up 52% from $198M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital's Q1 2015 filing shows 7 new, 5 increased, 5 reduced and 6 closed positions. Its largest new stake was Epizyme, Inc: 1,580,400 shares worth $29.7M. The largest sale was Sage Therapeutics, an estimated $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q1 2015 buy was Epizyme, Inc: 1,580,400 shares worth $29.7M.
  • EcoR1 Capital added most to Atara Biotherapeutics in Q1 2015, an estimated $17.9M increase.
  • EcoR1 Capital's biggest Q1 2015 reduction was Sage Therapeutics, cutting an estimated $16.3M.
  • EcoR1 Capital fully exited MacroGenics in Q1 2015, selling an estimated $15.9M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $300M portfolio in Q1 2015.
  • EcoR1 Capital opened 7 new positions and closed 6 in Q1 2015.
  • EcoR1 Capital's portfolio value rose 52% quarter-over-quarter to $300M.

Based on EcoR1 Capital's 13F filing for Q1 2015, filed 15 May 2015.